Related Experiment Video

Updated: May 5, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K

New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor

Jessica D Daley1, Susan L Whiteway2, Christine M Heske3

  • 1Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Pediatric Blood & Cancer
|August 29, 2025
PubMed

Insights

Outcomes for relapsed Ewing sarcoma are poor, necessitating novel treatment strategies. A task force evaluated new agents and trial designs to improve future clinical trials for relapsed Ewing sarcoma.

Area of Science:

  • Pediatric Oncology
  • Sarcoma Research
  • Clinical Trial Design

Background:

  • Relapsed Ewing sarcoma has consistently poor patient outcomes.
  • There is a critical need for innovative treatment approaches for relapsed Ewing sarcoma.
  • Existing clinical trial designs may present limitations for evaluating new therapies.

Purpose of the Study:

  • To systematically evaluate agents for future clinical trials in relapsed Ewing sarcoma.
  • To summarize limitations of common clinical trial designs for relapsed Ewing sarcoma.
  • To propose novel approaches for studying promising agents in clinical trials for relapsed Ewing sarcoma.

Main Methods:

  • Convening of the Children's Oncology Group Bone Tumor Committee's New Strategies for Ewing Sarcoma Task Force.
  • Systematic evaluation of potential therapeutic agents for relapsed Ewing sarcoma.
  • Analysis of common clinical trial designs and their limitations.

Main Results:

  • Identification of agents for potential inclusion in future Phase II or III clinical trials.
  • Summary of challenges and limitations associated with current trial methodologies.
  • Development of recommendations for improved clinical trial strategies.

Conclusions:

  • Future clinical trials require innovative designs to effectively evaluate new agents for relapsed Ewing sarcoma.
  • Strategic planning is essential to advance treatment options for this challenging pediatric cancer.
  • The task force's work provides a roadmap for improving the efficacy of future clinical investigations.
Keywords:
AYAEwing sarcomarelapse

More Related Videos

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

8.4K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K